BB Biotech reported Q3 net profit of CHF 448m, reversing a CHF 157m loss in Q3 2024. NAV rose 24%, outperforming the Nasdaq Biotech Index (+15.7%), while the share price increased by 20%. The quarter benefited from a sector-wide recovery, renewed M&A activity and improved funding conditions following the Fed’s September rate cut.
LÄS MER